On the 23rd of June, ADMA Biologics announced that it had elected Martha J. Demski to its Board of Directors.
The biopharmaceutical company, which develops and commercializes plasma-derived, human immune globulins, revealed that the decision was officially made in their Annual Shareholder Meeting, which was held on the 18th of June.
ADMA is a renowned biopharmaceutical company that collects source plasma (plasma donated by voluntary donors) and uses it to develop and manufacture FDA-approved plasma-based therapies. These therapies are invaluable to patients suffering from rare, often fatal conditions such as immune deficiency disorders or other infectious diseases.
Given this, the election of Demski seems perfectly reasonable. Demski has more than 35 years of experience in driving growth and financial strategies for life-science companies. She has served as Senior Vice President and CFO of Ajinomoto Althea Inc., which is today Ajinomoto Bio-Pharma Services. Prior to this, she served as the interim COO and CFO of Sidney Kimmel Cancer Center (SKCC). In addition, Demski has more than 13 years of experience with prominent financial institutions including Bank of America and the US Trust.
“Martha has a long track record of success serving in executive leadership roles in both finance and manufacturing, as well as on the Boards of several leading biotechnology companies,” said Steven A. Elms, Chairman of the Board of ADMA Biologics. “She brings to ADMA over 35 years of experience in the biotechnology sector making her an invaluable addition to our Board. On behalf of the Board and the entire management team, we welcome her and look forward to working with her in the years ahead.”
Currently, Demski serves as Chairman of the Board of Chimerix Inc., a biopharmaceutical company that develops oral antiviral therapeutics for patients in the US. As Elms remarked, she is also a Board Member of several life-science companies such as Equillium Inc.
She believes that given ADMA’s latest products (BIVIGAM and ASCENIV) and expansion of plasma collection facilities, it is “an exciting story in biotechnology and is well-positioned for substantial growth.”
“I look forward to bringing my extensive experience in financial strategy and business operations to the ADMA Board and I look forward to working with the entire team as we continue to tirelessly work towards our goal of manufacturing and commercializing novel immunoglobulin products for patients at risk for infection,” she added.
Give someone the chance to live a happier and healthier life. Donate your plasma. Find more information here.